HOME >> MEDICINE >> NEWS
Study Demonstrates Safety & Effectiveness Of Asthma Drug

Hershey, Pa. -- The major study of mild asthma reported in the September 19 issue of the New England Journal of Medicine ends a five-year debate about appropriate use of medication for treating mild asthma.

The results show that the commonly prescribed inhalant drug, albuterol, should be used only on an as-needed basis for patients with mild asthma. Regularly scheduled use of albuterol is not risky, but neither is it necessary, according to co-investigator Clifford W. Zwillich, M. D., professor and chief of pulmonary and critical care at Penn State's Milton S. Hershey Medical Center.

Puffing on the inhalant only during an attack of coughing or wheezing is sufficient for mild asthmatics, according to Zwillich. Data collection and statistical analysis for the multi-center study was designed and managed by Vernon M. Chinchilli, Ph.D., of the Center for Biostatistics and Epidemiology at Hershey.

Many of the more than 7 million Americans with mild asthma take albuterol as a regular medication. The inhalant is a beta-agonist that relaxes smooth muscles of the airways. It is sold under the brand names of Ventolin and Proventil.

The study also demonstrates that asthma patients continue to have a good response to inhaled beta-agonists, even after months of daily use, contrary to earlier reports.

Principal investigator Vernon M. Chinchilli, Ph.D., professor of biostatistics at Hershey, masterminded the design for collection, management and analysis of the data from patients at five medical centers. The work was coordinated by his team of researchers at the Asthma Clinical Research Network (ACRN) Data Coordinating Center (DCC) based at Hershey's Center for Biostatistics. ACRN is funded by the National Heart, Lung and Blood Institute (NHLBI).

The results of the study were reported in the article, "Comparison of Regularly Scheduled with As-Needed Use of Albuterol in Mild Asthma," in the September 19 issue of the New England Journal of Medicine, a
'"/>

Contact: Gail Brown
gxg14@psu.edu
717-531-8604
Penn State
24-Sep-1996


Page: 1 2 3 4

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study Demonstrates Safety Effectiveness Asthma Drug

(Date:5/23/2013)... THURSDAY, May 23 (HealthDay News) -- A modified ... help fight brain tumors, preliminary research suggests. ... investigational therapy, known as PVSRIPO, uses an engineered ... normal cells, but attacks cancer cells. The therapy ... most common and aggressive brain tumor, they said. ...
(Date:5/23/2013)... when a woman harried by hot flashes says she,s ... published online in Menopause , the journal of ... objective tests that what these women say about their ... showed that hot flashes were related to memory problems, ... there was a relationship between hot flashes and what ...
(Date:5/23/2013)... Williamsport, PA (PRWEB) May 23, 2013 ... Sitter® Teaching Site, offering a comprehensive babysitting training course ... nationally-recognized program was developed by Indianapolis pediatrician Dr. Patricia ... in the care of an adult sitter who didn’t ... a well-rounded youth development program with a medical basis ...
(Date:5/23/2013)... drug about to be tested in a clinical trial ... treatment for Alzheimer,s disease has failed to work with ... patients, according to results of a study by University ... of neuroscience affiliated with the Evelyn F. and William ... emphasized the importance of verifying promising research results before ...
(Date:5/23/2013)... 2013 The Rottenstein Law Group LLP, ... created the Tylenol Lawsuit Information Center at http://www.rotlaw.com/tylenol ... and those who are considering filing lawsuits. , ... cause severe liver damage, according to a 2009 report ... the “safety communication,” the FDA warned consumers against using ...
Breaking Medicine News(10 mins):Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2
(Date:5/23/2013)... 23, 2013  Spring Bank Pharmaceuticals, Inc., a biopharmaceutical ... infections, today announced that it has initiated dosing in ... once daily, oral therapy for the treatment of HCV ... and is designed to assess both the safety and ... first-in-class drug for the treatment of chronic HCV infections ...
(Date:5/23/2013)... FREDERICK, Md. , May 23, 2013  BioElectronics ... safe consumer medical devices, comments on the FDA panel ... Public Advisory Panel Reclassification – Pulsed Shortwave Therapy Meeting ... Gaithersburg, MD , USA.  The focus of the ... instructed the panel to focus solely on the application ...
(Date:5/23/2013)... , May 23, 2013 Halozyme Therapeutics, ... the appointment of David A. Ramsay ... was most recently Vice President, Corporate Development at ... "With his established financial management experience ... by working in our commercial group for the ...
Breaking Medicine Technology:Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3BioElectronics and Pulsed Shortwave Therapy Make Progress 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2
Cached News: